Comparative Pharmacokinetics of Seven Major Compounds in Normal and Atherosclerosis Mice after Oral Administration of Simiao Yong'an Decoction
- PMID: 35529931
- PMCID: PMC9071858
- DOI: 10.1155/2022/4604601
Comparative Pharmacokinetics of Seven Major Compounds in Normal and Atherosclerosis Mice after Oral Administration of Simiao Yong'an Decoction
Abstract
Simiao Yong'an decoction (SMYAD), a classic traditional Chinese medicine formula, has been used to treat atherosclerosis (AS) in clinical in China, but its therapeutic mechanism and pharmacodynamic material basis are not clear. In this study, the AS model was caused by a high-fat diet and perivascular carotid collar placement (PCCP), and SMYAD was orally administered to the model and normal mice. A rapid, sensitive, selective, and reliable method using ultrahigh-performance liquid chromatography (UHPLC) system combined with a Q Exactive HF-X mass spectrometer (UHPLC-Q Exactive HF-X MS) was established and validated for the simultaneous determination of seven compounds, including harpagide, chlorogenic acid, swertiamarin, sweroside, angoroside C, liquiritin, and isoliquiritigenin in the plasma of normal and AS mice. The specificity, linearity, precision, accuracy, recovery, and stability of the method were all within the acceptable criteria. The results showed that some pharmacokinetic behaviors of harpagide, chlorogenic acid, and isoliquiritigenin were significantly different among the two groups of mice. The specific parameter changes were harpagide (AUC0-t and AUC0-∞ were 11075.09 ± 2132.38 and 16221.95 ± 5622.42 ng·mL-1·h, respectively; CLz/F was 2.45 ± 0.87 L/h/mg), chlorogenic acid (t 1/2 was 21.59 ± 9.16 h; AUC0-∞ was 2637.51 ± 322.54 ng·mL-1·h; CLz/F was 13.49 ± 1.81 L/h/mg) and isoliquiritigenin (AUC0-t and AUC0-∞ were 502.25 ± 165.65 and 653.68 ± 251.34 ng·mL-1·h, respectively; CLz/F was 62.16 ± 23.35 L/h/mg) were altered under the pathological status of AS. These differences might be partly ascribed to the changes in gastrointestinal microbiota, nonspecific drug transporters, and cytochrome P450 activity under the AS state, providing research ideas and experimental basis for pharmacological effects and pharmacodynamic material basis.
Copyright © 2022 Ke-han Sun et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Study on the Plasma Protein Binding Rate and Compatibility Regularity of the Constituents Migrating to Blood of Simiao Yong'an Decoction.Curr Drug Metab. 2020;21(12):979-993. doi: 10.2174/1567201817666200731170731. Curr Drug Metab. 2020. PMID: 32735517
-
[Comprehensive identification of metabolites and metabolic characteristics of luteolin and kaempferol in Simiao Yong'an Decoction in rats by UHPLC-LTQ-Orbitrap MS/MS].Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):6191-6199. doi: 10.19540/j.cnki.cjcmm.20230621.201. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114226 Chinese.
-
[Exploration on origin of Simiao Yong'an Decoction].Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(5):1209-1212. doi: 10.19540/j.cnki.cjcmm.20200103.501. Zhongguo Zhong Yao Za Zhi. 2020. PMID: 32237467 Chinese.
-
[Interpretation of connotation of Simiao Yong'an Decoction based on severe cases and modern pathophysiological mechanisms and experience in treating diabetic foot with infection, sepsis, and arteriosclerosis obliterans in critical care medicine].Zhongguo Zhong Yao Za Zhi. 2025 Jan;50(1):267-272. doi: 10.19540/j.cnki.cjcmm.20240924.501. Zhongguo Zhong Yao Za Zhi. 2025. PMID: 39929667 Review. Chinese.
-
Systematic investigation of the material basis, multiple mechanisms and quality control of Simiao Yong'an decoction combined with antibiotic in the treatment of sepsis.Phytomedicine. 2023 Jul 25;116:154910. doi: 10.1016/j.phymed.2023.154910. Epub 2023 May 29. Phytomedicine. 2023. PMID: 37267690
Cited by
-
Mechanism of Simiao Decoction in the treatment of atherosclerosis based on network pharmacology prediction and molecular docking.Medicine (Baltimore). 2023 Sep 8;102(36):e35109. doi: 10.1097/MD.0000000000035109. Medicine (Baltimore). 2023. PMID: 37682164 Free PMC article.
References
-
- Arnett D. K., Blumenthal R. S., Albert M. A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Journal of the American College of Cardiology . 2019;74(10):1376–1414. doi: 10.1016/j.jacc.2019.03.009. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous